CETP inhibition clings to life as Roche’s dal-OUTCOMES post mortem proves inconclusive
This article was originally published in Scrip
A shadow continued to fall over cholesterol ester transfer protein (CETP) inhibitors, as the full results of Roche’s doomed dal-OUTCOMES study were presented at the American Heart Association meeting in Los Angeles, suggesting that a small increase in blood pressure with dalcetrapib may have done for the drug
You may also be interested in...
A BLA filing for Zynteglo in beta-thalassemia is expected in the second half of 2020 instead of the first half, but the first commercial patient in the EU will be treated in the first half of this year.
Private Company Edition: While venture capital invested in the industry dropped in 2019, the number of deals rose as investors funded more early-stage VC rounds. Money continues flowing to large deals as well, including $105m for ALX Oncology and $98m for CANbridge.
Public Company Edition: Five out of six drug developers and a CRO have seen their values spike immediately after going public this month. Also, Moderna floats a $500m offering, Revance proposes a $20m note sale, and Nestle invests another $200m in Aimmune.